Stanford researchers have developed a new technology, Variant-FlowFISH, to enable high-throughput, highly sensitive measurements of how variants, introduced via CRISPR, affect gene expression.
Stanford researchers have developed a new, low-cost method for tumor methylation profiling that enables tumor classification even from low amounts of fragmented DNA characteristic of liquid biopsies.
Stanford inventors have engineered a bacteriophage as a novel class of UV-absorbing particles. These agents may provide an environmentally friendly alternative to current sunscreen products, which are synthetically produced with petroleum products and damaging to marine life.
The Longaker lab at Stanford University has recently discovered that local injection of the drug Verteporfin after wounding can reduce scarring, improve the strength of healed skin, and regrow the hair follicles and sweat glands that are usually lost during the scarring proces
Stanford researchers have developed improved methods for producing mRNAs. Efficient, robust and high fidelity production of mRNAs is critical for obtaining pharmaceutical quality vaccines, viruses and expression constructs, and for eliminating noise due to batch variation.
Stanford researchers have developed improved methods for producing mRNAs. Efficient, robust and high fidelity production of mRNAs is critical for obtaining pharmaceutical quality vaccines, viruses and expression constructs, and for eliminating noise due to batch variation.
Inventors at Stanford University have developed a light-based 3D printing system that achieves high printing resolutions and fast printing speeds with cell-compatible natural protein biomaterials when compared to existing methods.
Stanford inventors have developed a novel diagnostic tool that identifies distinct immune signatures in the peripheral blood of osteoarthritis patients using mass cytometry (CyTOF) and applied machine learning.
Skin wounds invariably heal by developing fibrotic scar tissue, which can result in devastating disfigurement, growth restriction and permanent functional loss.
Stanford researchers have developed technology enabling pooling and simultaneous testing of engineered T cells from multiple human donors. This invention increases scale and reduces costs for diagnostic, and pre-clinical development of engineered T cell therapies.
Stanford researchers have engineered retroviral and virus-like delivery systems for producing universal pseudotyped vehicles for cell and gene therapies.